- Conditions
- Early Alzheimer's Disease
- Interventions
- Lecanemab IV, Placebo, Lecanemab SC
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 112
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Aging
- Interventions
- repetitive transcranial magnetic stimulation (rTMS)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Aging, Mental Disorder, Eating, Healthy, Physical Inactivity, Prodromal Symptoms, Sleep, Alzheimer Disease, Dementia, Circadian Rhythm Disorders
- Interventions
- Behavioral Self-Monitoring + Motivational Interviewing
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- LY3372689, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 35
- States / cities
- Canoga Park, California • Fresno, California • Irvine, California + 30 more
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Interventions
- AADvac1, Donanemab
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
- Conditions
- Alzheimer's Disease
- Interventions
- Avagacestat, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Mild Cognitive Impairment, Prodromal Alzheimer's Disease
- Interventions
- Placebo Oral Tablet, AGB101 220 mg tablet
- Drug
- Lead sponsor
- AgeneBio
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Laguna Hills, California • Oceanside, California + 20 more
- Conditions
- Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
- Interventions
- Active rTMS, Sham rTMS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more
- Conditions
- Alzheimer's Disease
- Interventions
- Elenbecestat, Placebo
- Drug
- Lead sponsor
- Eisai Co., Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 2,212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 88
- States / cities
- Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more
- Conditions
- Alzheimer's Disease
- Interventions
- Crenezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 806 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more
- Conditions
- Alzheimers Disease
- Interventions
- RO7126209, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more
- Conditions
- Prodromal Alzheimer's Disease
- Interventions
- Partnered Rhythmic Rehabilitation (PRR), Group walking (WALK)
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more
- Conditions
- Alzheimer Disease, Dementia, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Interventions
- Financial Incentives, Message
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 44,844 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Martinez, California
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Senicapoc, Placebo Tablet
- Drug · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Sacramento, California • Walnut Creek, California
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Novoic Limited
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Santa Ana, California
- Conditions
- Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Subjective Cognitive Complaints
- Interventions
- Digital Memory Notebook (DMN) Application
- Behavioral
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
- Conditions
- Alzheimer's Disease
- Interventions
- Solanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 98
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 80 more
- Conditions
- Mild Cognitive Impairment, Prodromal Alzheimer's Disease
- Interventions
- AGB101, Placebo
- Drug
- Lead sponsor
- AgeneBio
- Industry
- Eligibility
- 55 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,053 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Irvine, California • Sacramento, California + 29 more
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Interventions
- AADvac1, Tau2
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Providence, Rhode Island • Nashville, Tennessee